Latest News about MOLN
Recent news which mentions MOLN
34 Stocks Moving In Tuesday's Mid-Day Session
January 18, 2022
From Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 18, 2022
From Benzinga
From InvestorPlace
23 Stocks Moving in Tuesday's Pre-Market Session
January 18, 2022
From Benzinga
52 Biggest Movers From Friday
January 18, 2022
From Benzinga
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
January 16, 2022
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 14, 2022
From Benzinga
From Benzinga
30 Stocks Moving In Friday's Mid-Day Session
January 14, 2022
From Benzinga
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
January 14, 2022
From Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 14, 2022
From Benzinga
From InvestorPlace
18 Stocks Moving in Friday's Pre-Market Session
January 14, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
January 13, 2022
From Benzinga
48 Biggest Movers From Yesterday
January 12, 2022
From Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 11, 2022
From Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
January 11, 2022
From Benzinga
From InvestorPlace
21 Stocks Moving in Tuesday's Pre-Market Session
January 11, 2022
From Benzinga
60 Biggest Movers From Yesterday
January 11, 2022
From Benzinga
Why Molecular Partners Stock Crushed the Market Today
January 10, 2022
From Motley Fool
Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge
January 10, 2022
From Benzinga
45 Stocks Moving In Monday's Mid-Day Session
January 10, 2022
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 10, 2022
From Benzinga
From InvestorPlace
Here’s the market move Cathie Wood says is ‘ridiculous’ as her flagship fund sputters
January 10, 2022
From MarketWatch
20 Stocks Moving in Monday's Pre-Market Session
January 10, 2022
From Benzinga
Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data
January 10, 2022
From Benzinga
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.